VOLUME 6A Procedures for marketing authorisation
|
|
- Tyrone Leonard
- 5 years ago
- Views:
Transcription
1 EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, ENTR/F2/KK D(2007) Revision September 2007 NOTICE TO APPLICANTS VETERINARY MEDICINAL PRODUCTS VOLUME 6A Procedures for marketing authorisation CHAPTER 3 COMMUNITY REFERRAL PROCEDURES September 2007 This Chapter 3 Community Referral Procedures will be included in The Rules governing Medicinal Products in the European Union The Notice to Applicants Volume 6A Procedures for marketing authorisation Rue de la Loi 200, B-1049 Bruxelles/Wetstraat 200, B-1049 Brussel - Belgium - Office: BREY 10/073. Telephone: direct line (+32-2) , switchboard Fax: (+32-2) Karin.Krauss@ec.europa.eu 1
2 CHAPTER 3 Community Referral Procedures September 2007 Legal Basis and Purpose Referrals under Articles 33, 34, 35, 39 and 40 of Directive 2001/82/EC Introduction.2 2. Article 33(4) of Directive 2001/82/EC ( Mutual Recognition and Decentralised referral ) Article 34 of Directive 2001/82/EC ( Divergent decision referral ) Article 35 of Directive 2001/82/EC ( Community interest referral ).6 5. Articles 39 and 40 of Directive 2001/82/EC ( Follow-up referrals ).8 6. Unilateral Action by Member States in urgent cases Procedural elements Decision making procedure at Community level Consequences of a commission decision following a referral to the CVMP.16 Annex: Notification forms..19 Legal Basis and purpose Community pharmaceutical legislation has created a binding Community mechanism which may be invoked on the basis of the following articles: 1. Article 33 of Directive 2001/82/EC ( Mutual Recognition and Decentralised referral ) 2. Article 34 of Directive 2001/82/EC ( Divergent decision referral ) 3. Article 35 of Directive 2001/82/EC ( Community interest referral ) 4. Articles 391 and 40 of Directive 2001/82/EC ( Follow-up referrals ) Whenever this binding mechanism is invoked, a scientific evaluation of the matter is undertaken by the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency s (EMEA/Agency). These referrals lead to an opinion from which the Commission issues a single decision addressed to all Member States which is reported for information to the applicant(s) or marketing authorisation holder(s). This chapter sets out the details for the above procedures. 1 Referrals under Article 5(11), 6(12) or 6(13) of Regulation (EC) No 1084/
3 REFERRALS UNDER ARTICLES 33, 34, 35, 39 AND 40 OF DIRECTIVE 2001/82/EC 1. Introduction The specific conditions under which a referral procedure may be started and those entitled to trigger such referral differ in each of the cases and are specified in detail in sections 2 to 5. Under certain, well-defined circumstances (where urgent action to protect human or animal health or the environment is necessary) Member States may take unilateral action whilst awaiting the outcome of a. These cases are illustrated in section 6. The procedural elements of the referral procedure to the CVMP are laid down in Articles 36, 37 and 38 of Directive 2001/82/EC. These procedural elements are the same for all types of referrals to the CVMP and are described in section Article 33(4) of Directive 2001/82/EC ( Mutual Recognition and Decentralised referral ) 2.1 Basic principles If the Member States involved in a mutual recognition or decentralised procedure fail to reach an agreement within the 60-day period in the coordination group procedure of Article 33(1) to (3) of Directive 2001/82/EC, a referral according to Article 33(4) shall be triggered2. The referral shall be triggered by the reference Member State, on the grounds of potential serious risk to human or animal health or to the environment, where no agreement was reached during the coordination group procedure on the assessment report, the summary of product characteristics, or the labelling and the package leaflet, prepared by that reference Member State. For a description of the coordination group procedure, see Chapter 2, section 5 of the Notice to Applicants. For the definition of potential serious risk to human or animal health or to the environment, the Commission has adopted a guideline, available at Can the application be withdrawn or the referral be stopped? It is in the public interest and in the interest of the Community that questions raised on potential serious risks to human or animal health or to the environment are answered, and that all veterinary medicinal products authorised in the Community fulfil the requirements of quality, safety and efficacy. An application for mutual recognition of a marketing authorisation or an application in the decentralised procedure may be withdrawn by the applicant(s)/marketing authorisation holder(s) at any time in any Member State. After a potential serious risk to human or animal health or to the environment has been raised in accordance with Article 33(1) by a concerned Member State, a withdrawal of the 2 Homeopathic veterinary medicinal products subject to a special simplified registration procedure foreseen in Article 17 of Directive 2001/82/EC may not be referred to the CVMP. If agreement within the veterinary coordination group procedure is not reached, national authorities are competent to decide on the registration. 3
4 application in some of the Member States will not stop the matter from being discussed within the Coordination Group (CMD(v)) and, eventually, from a referral procedure being triggered. The referral can only be stopped if the applicant(s)/marketing authorisation holder(s) withdraws the application/authorisation in all EEA Member States. 2.3 Procedural steps leading to an Article 33 referral If the Member States do not reach agreement in the coordination group procedure, the reference Member State will refer the matter to the Agency for the application of the procedure laid down in Articles 36, 37 and 38 of Directive 2001/82/EC. In the referral, the reference Member State shall provide the Agency with a detailed statement of the matter(s) on which the Member States concerned have been unable to reach agreement and the reasons for their disagreement. The matter(s) referred to the Agency must be based on potential serious risk to human or animal health or to the environment and should be precise. A notification form for a referral to the CVMP/EMEA is added in the Annex. The applicant/marketing authorisation holder is provided with a copy of this information. This detailed statement should focus on the following essential elements: i. description of the product: the latest available summary of product characteristics, labelling and package leaflet as achieved during the coordination group procedure; ii. description of the remaining areas of disagreement, giving a clear statement of the issues at referral, including in particular the reasons for disagreement and a proposal for question(s) to be addressed by the applicant. In addition, the reference Member State should provide to the Agency a consolidated report addressing the following: i. description of the scientific discussion during the various stages of the mutual recognition/decentralised procedure between the reference Member State and concerned Member State(s), including a brief summary of the resolution of other major issues between day 0 and day 60 of the coordination group procedure and a summary of the discussions and outcomes of the coordination group procedure; ii. initial assessment report of the reference Member State and an updated assessment report following the coordination group procedure. This report will be forwarded to the applicant(s)/marketing authorisation holder(s) at the start of the procedure. As soon as the applicant(s)/marketing authorisation holder(s) is/are informed that the matter has been referred to the Agency, the applicant(s)/marketing authorisation holder(s) shall forward to the Agency a copy of the application he/they had submitted to the competent authorities of the Member States concerned, containing the information and documents referred to in Articles 12, 13, 13a, 13b, 13c or 13d and 14 of Directive 2001/82/EC. 2.4 Scope of the referral The CVMP is called upon to issue an opinion on the concerns that, in accordance with the assessment report and product information proposed by the reference Member State, the authorisation of the veterinary medicinal product concerned might present a potential serious risk to human or animal health or to the environment. 4
5 The term risk related to the use of veterinary medicinal products is defined in Directive 2001/82/EC, Article 1(19), as any risks relating to the quality, safety or efficacy of the veterinary medicinal product as regards animal or human health and any risk of undesirable effects on the environment. In addition, on the basis of Article 33(2) of Directive 2001/82/EC, the Commission has adopted a guideline to define a potential serious risk to human or animal health or to the environment, available at If the CVMP is asked about potential serious risk to human or animal health or to the environment concerns, it may consider aspects subsequently arising during the assessment, necessary to draft the summary of product characteristics, labelling and package leaflet which will be annexed to the opinion of the CVMP and to the decision of the Commission as provided in Articles 36, 37 and 38 of Directive 2001/82/EC. In the case of a positive outcome of the referral a summary of product characteristics, labelling and the package leaflet will be annexed to the CVMP opinion. In cases where the assessment of the CVMP is restricted to limited parts of the summary of product characteristics, labelling and package leaflet it will be possible to have in the annex of the opinion only those parts which were subject to amendment during the referral, together with a statement that, for the remaining parts, the summary of product characteristics, labelling and package leaflet are the final versions achieved during the coordination group procedure. It is also possible that the assessment of the CVMP concludes that no modifications of the summary of product characteristics, labelling and package leaflet are needed. In such case, the annex of the opinion shall reflect that conclusion. However, in situations where the matters referred demand intervention across several sections of the SPC a full summary of product characteristics, labelling and package leaflet will be annexed to the decision. Even in such cases, the invented names, the names of the marketing authorisation holders and the legal supply status may be different between Member States concerned. 2.5 Marketing authorisations before completion of the referral procedure According to Article 33(6), when there is a failure to reach an agreement within the coordination group procedure, Member States that have approved the assessment report, the draft summary of product characteristics and the labelling and package leaflet of the reference Member State may, at the request of the applicant, authorise the veterinary medicinal product without waiting for the outcome of the procedure laid down in Article 36. In that event, the authorisation granted shall be without prejudice to the outcome of that procedure. The summary of product characteristics, the labelling and the package leaflet to be covered by those marketing authorisations shall be the ones proposed by the reference Member State or, when these have been subject to amendments agreed within the coordination group procedure, the last version agreed therein. 5
6 3. Article 34 of Directive 2001/82/EC ( Divergent decision referral ) 3.1 Basic principles Any Member State, the Commission or the applicant/marketing authorisation holder of a particular veterinary medicinal product may trigger a referral if divergent decisions on the authorisation, suspension or revocation of a particular veterinary medicinal product have been taken by two or more Member States. The divergences are to be identified, in the notification form, in a sufficiently precise manner. Article 34(1) of Directive 2001/82/EC may apply to all marketing authorisations which have been issued by Member States, both so-called purely national marketing authorisations (which have not been subject to any Community procedures) and national marketing authorisations which have been issued following a mutual recognition or decentralised procedure. Article 34(1) may be invoked, for instance, in the following cases: Where a particular veterinary medicinal product has been nationally authorised in two or more Member States and the authorisations diverge; Where a particular veterinary medicinal product, with a national marketing authorisation in some or all the Member States, is suspended or revoked for quality, safety or efficacy reasons in some -but not all- Member States; Where a particular veterinary medicinal product is nationally authorised in some or all Member States and one of the authorisations is subsequently varied, introducing a divergence versus the other national authorisations. 3.2 Can the referral be stopped? The referral can only be stopped if marketing authorisation holder(s) withdraw the concerned marketing authorisations from all EEA markets. This condition applies regardless of whether the procedure was triggered by the European Commission, a Member State or the marketing authorisation holder. 3.3 Procedural steps leading to an Article 34 referral The referrer (Member State, applicant/marketing authorisation holder or the Commission) sends the question to the CVMP for consideration, together with a detailed explanation of the issue(s) raised. A notification form for a referral to the CVMP/EMEA is provided in the Annex to this Chapter. The divergences have to be presented and described to support the notification of the referral. If the referrer is a Member State or the Commission, the applicant/marketing authorisation holder must be informed of the referral. If the referrer is an applicant/marketing authorisation holder, in advance of making a referral under Article 34(1), he is recommended to have a pre-referral meeting with the EMEA. Prereferral meetings are also possible in cases where the referrer is a Member State or the Commission. 6
7 Following notification of the referral, the applicant(s)/marketing authorisation holder(s) and the Member States concerned forward to the Agency any information relevant to the referral. In particular, the applicant/ marketing authorisation holder is requested to forward copies of the relevant parts of the dossiers of the national marketing authorisations/applications in the Member States concerned. 3.4 Scope of the referral The CVMP is called upon to issue an opinion on the area(s) of divergence amongst the national decisions, on the basis of the question referred to it relating to a particular veterinary medicinal product. The scope of the referral is to resolve the divergences between the national decisions, and therefore this referral leads to a full harmonisation of the summary of product characteristics, labelling and package leaflet. Certain differences may, however, remain, such as invented names, names of the marketing authorisation holders and legal supply status. 4. Article 35 of Directive 2001/82/EC ( Community interest referral ) 4.1 Basic principles Article 35 states that Member States, the Commission or the applicant(s)/marketing authorisation holder(s) of the concerned veterinary medicinal product shall trigger a referral whenever the interests of the Community are involved, before a decision is taken on a request for a marketing authorisation, or on the suspension, or revocation of a marketing authorisation or on any other variation to the terms of a marketing authorisation which appears necessary in particular to take into account pharmacovigilance information. This referral is to be started in specific cases where the interests of the Community are involved. The expression interest of the Community refers particularly to the interests of human or animal health or of the environment related to veterinary medicinal products on the market in the Community in the light of quality, safety and efficacy data and to free movement of products within the Community. Whenever a Member State or the Commission or applicant(s)/marketing authorisation holder(s) invokes Article 35, it should duly identify the relevant interests of the Community and set out how they are involved. An Article 35 referral may concern only one veterinary medicinal product or a range or class of veterinary medicinal products (an active substance, which is present in several different veterinary medicinal products with different invented names and different marketing authorisation holders, or different active substances and veterinary medicinal products belonging to the same therapeutic class) - so-called class referral. When the referral concerns a range of veterinary medicinal products or a therapeutic class the specific provisions of Article 35(2) will apply. In this case, the legislation expressly states that the Agency/CVMP may limit the procedure to certain specific parts of the authorisation. 4.2 Can the referral be stopped? Once the referral is triggered, the referral can only be stopped if applicant(s)/marketing authorisation holder(s) withdraw the concerned applications/authorisations from all EEA 7
8 markets. This condition applies regardless of whether the procedure was triggered by the European Commission, a Member State or the marketing authorisation holder. 4.3 Procedural steps leading to an Article 35 referral The referrer (Member State(s), applicant(s)/marketing authorisation holder(s) or the Commission) clearly identifies the question which is referred to the CVMP for consideration together with a detailed explanation of the issue(s) raised and how the Community interests are involved. A notification form for a referral to the CVMP/EMEA is provided in the Annex to this Chapter. If the referrer is a Member State or the Commission, the applicant(s)/marketing authorisation holder(s) must be informed on the issues raised in the referral. If the referrer is an applicant/marketing authorisation holder, in advance of making a referral under this Article, he is recommended to have a pre-referral meeting with the EMEA. Prereferral meetings between the applicant/marketing authorisation holder and the EMEA are also possible in cases where the referrer is a Member State or the Commission. Following the start of the referral procedure, the Member States and the applicant(s)/marketing authorisation holder(s) shall forward to the Committee all relevant information relating to the veterinary medicinal product(s). 4.4 Scope of the referral Referral relating to a specific veterinary medicinal product The CVMP is called upon to issue an opinion on a matter involving Community interests, on the basis of a question referred to it. However, the CVMP may consider aspects other than those explicitly mentioned in the referral which are necessary to evaluate quality, safety and efficacy of the veterinary medicinal product under consideration, and which are necessary to produce a fully harmonised summary of product characteristics, labelling and package leaflet to be annexed to its opinion. Certain differences may, however, remain, such as invented names, names of the marketing authorisation holders and legal supply status Class referral Where the referral to the Committee concerns a range of veterinary medicinal products or a therapeutic class, the Agency may limit the procedure to certain specific parts of the authorisation. If the Agency decides to limit the procedure in this way, only specific sections, or parts of them, of the summary of product characteristics will be harmonised with the corresponding changes to the relevant package leaflet section and labelling. This has consequences, in that an Article 39 referral may only apply to those veterinary medicinal products if they were covered by the authorisation procedures referred to in Chapter 4 of Directive 2001/82/EC (i.e. mutual recognition and decentralised procedures) or when, having been granted purely national marketing authorisations, they have been subject to a referral3. Where a Community interest referral procedure related to so-called purely 3 With the exception of a partial harmonisation within the meaning of paragraphs 48 and 49 of the judgement of the European Court of Justice in case C-39/03 P "Artegodan" (national marketing authorisations granted on a purely national basis outside mutual recognition subject to a harmonisation limited to the clinical particulars of the summary of product characteristics). 8
9 national marketing authorisations has been limited to specific parts of the authorisations, Member States may continue to vary them using national procedures. Centrally authorised veterinary medicinal products belonging to a class subject to an Article 35 referral may not be part of the referral procedure itself but may be handled where necessary via a parallel procedure according to Article 45 of Regulation (EC) No 726/2004 triggered by the Commission. 5. Articles 39 and 40 of Directive 2001/82/EC ( Follow-up referrals ) 5.1 Basic principles These referrals, known as follow-up referrals, may be triggered by a Member State or the marketing authorisation holder in the respect of veterinary medicinal products which have been granted a marketing authorisation via the mutual recognition or decentralised procedures or which have been the subject of harmonisation as a result of a referral procedure. Products which have been granted purely national marketing authorisations and which were subject to a subsequent partial harmonisation limited only to the clinical particulars of the summary of product characteristics (within the meaning of paragraphs 48 and 49 of the judgement of the European Court of Justice in case C-39/03) may not be subject to follow-up referrals. A Member State may trigger a follow-up referral in the following situations: Upon rejection of a Type IB variation, by reference to Article 39 of Directive 2001/82/EC and Article 5(11) of Regulation (EC) No 1084/2003; When mutual recognition by one or more national competent authorities of the draft decision of the Reference Member State on a Type II variation is not possible, by reference to Article 39 of Directive 2001/82/EC and Article 6(12) of Regulation (EC) No 1084/2003; When it considers a variation, suspension or revocation of a harmonised marketing authorisation necessary for the protection of human or animal health or the environment, by reference to Article 40 of Directive 2001/82/EC. The marketing authorisation holder may trigger a follow-up referral in the following situations: Upon rejection of a Type IB variation, by reference to Article 39 of Directive 2001/82/EC and Article 5(11) of Regulation (EC) No 1084/2003; When the competent authorities of the Member States concerned by the application are of the opinion that the Type II variation can not be accepted, by reference to Article 39 of Directive 2001/82/EC and 6(13) of Regulation (EC) No 1084/2003. Article 41 of Directive 2001/82/EC extends the scope of Articles 39 and 40 referrals to veterinary medicinal products authorised by Member States following an opinion of the CVMP given in accordance with Article 4 of Directive 87/22/EEC before 1 January 1995 (exconcertation veterinary medicinal products). 9
10 5.2 Can the referral be stopped? Once the referral is triggered, the referral can only be stopped if marketing authorisation holder(s) withdraw the concerned marketing authorisations from all EEA markets. The same condition applies if the procedure was triggered by the marketing authorisation holder. 5.3 Procedural steps leading to Articles 39 and 40 referrals For Article 39 and Article 40 referrals the procedural steps of Article 33 and Article 35 referrals apply in a similar manner, respectively. 5.4 Scope of the referral In accordance with the general principle that achieved harmonisation must be maintained, Community pharmaceutical legislation has created an arbitration mechanism which aims to resolve divergences arising between Member States AFTER harmonisation has been achieved. As provided for in Article 6(12) of Regulation (EC) No 1084/2003, the procedure referred to in Article 39(2) of Directive 2001/82/EC (i.e. the procedure for referral to CVMP) shall apply where it has not been possible to achieve agreement under the mutual recognition procedure for a variation. Article 40 applies where a Member State considers that the variation of a marketing authorisation which has been granted in accordance with the provision of Chapter 4 of Directive 2001/82/EC (mutual recognition or decentralised procedures) or its suspension or withdrawal is necessary for protection of human or animal health or of the environment. The CVMP is called upon to issue an opinion on the matter of variation of the terms of a marketing authorisation, its suspension or revocation, framed on a question referred to it. The CVMP should limit its opinion to the question referred, since harmonisation has already been achieved. However, the CVMP may consider aspects others than those explicitly mentioned in the referral, in those cases where the referral was initiated for the protection of human or animal health or for the environment, in so far it appears necessary to guarantee such protection. 6. Unilateral Action by Member States in urgent cases When concerns about a veterinary medicinal product have a European dimension (i.e. the product is authorised in more than one Member State) or are of Community interest, divergence between the Member States on the need to vary, suspend or revoke the marketing authorisation shall be resolved at European level, within the Community arbitration mechanisms described above. Unilateral national action is thus not acceptable. However, Community pharmaceutical legislation does recognise the need for unilateral measures by Member States where, in exceptional cases, urgent action is essential to protect human or animal health or the environment and until a definitive action is adopted. In accordance with Article 40 (2) of Directive 2001/82/EC, in these specific cases, the Member States may temporarily adopt national measures suspending the marketing and use of a veterinary medicinal product. They must inform the Commission, the Agency and the other Member States no later than the following working day not only of the urgent measure adopted but also of the reasons for such measure. 10
11 In addition it should be noted that Article 78(1) of Directive 2001/82/EC places an obligation on each Member State to inform the Agency, the other Member States and the marketing authorisation holder of the need of a variation, to restrict an indication or the availability, to amend the posology, or to add a contraindication or a new precautionary measure or the suspension or revocation of a marketing authorisation for any veterinary medicinal product even purely nationally authorised products resulting from the evaluation of pharmacovigilance data. Article 78(2) of Directive 2001/82/EC also allows Member States, where urgent action to protect human or animal health is necessary, to suspend the marketing authorisation of a specific veterinary medicinal product. In the event this action is taken, the Member State shall inform the Agency, the Commission and the other Member States no later than the following working day. When the Agency is informed, on the basis of Article 78(3), that a Member State is considering a variation in accordance with the specification above or a suspension or revocation of a marketing authorisation, or that urgent action was undertaken by a Member State, by suspending a marketing authorisation, the Agency shall prepare an opinion to address the issue. On the basis of such opinion, the Commission may request the Member States where the product is authorised to take temporary measures immediately, while waiting for the adoption of final measures, which shall follow the procedure foreseen in Article 89(3). 7. Procedural elements Notwithstanding the legal provisions described above (Articles 36, 37 and 38 of Directive 2001/82/EC as amended), it is recommended to take a number of preliminary procedural steps in order to streamline the operation of the procedure. In advance of making a referral, it is strongly encouraged that a notification is sent to the Agency by the applicant/marketing authorisation holder or Member State, including: The intention to submit a referral; Clear and concise identification of the question to be referred to the CVMP, indicating the veterinary medicinal product concerned, pharmaceutical forms and/or strengths, route of administration, target species, applicant(s)/ marketing authorisation holder(s); Proposal on documentation to be provided in support of the referral; Where appropriate, request for a meeting with the Agency to discuss regulatory and procedural issues linked to the referral. When an issue is referred to the CVMP, each Member State is asked to make available to the Agency before the end of the first CVMP meeting following the referral a list of the names of the veterinary medicinal product(s) affected by the referral (including pending applications), together with information on the respective applicant(s)/marketing authorisation holder(s), strength(s), pharmaceutical form(s), target species and route(s) of administration. In the case of Article 33 referrals triggered in the frame of a repeat use mutual recognition procedure, the list of the names of the veterinary medicinal product affected by the referral shall also include those authorised by the first mutual recognition procedure. 11
12 A Member State triggering a referral should submit all available information relating to the veterinary medicinal product and depending on the type of referral to the matter in question to the CVMP. In cases where the referral follows the revocation or the suspension of the marketing of a veterinary medicinal product in a Member State, that Member State should immediately forward all information relating to this action to the CVMP members, the competent authorities of the other Member States and the Agency. In the case of referrals initiated by (an) applicant(s)/marketing authorisation holder(s), the referral should be accompanied by expert reports/overviews which take into account legislation in force and which have been updated to include data supporting the reasons for referral. In addition the applicant(s)/marketing authorisation holder(s) should ensure that all available information relating to the matter in question is forwarded to the CVMP members, the competent authorities of the Member States and the Agency. To ensure a smooth implementation of the above-mentioned requirements, the Agency will inform the applicant(s)/marketing authorisation holder(s) for each referral on the documentation needed as well as on the number of copies to be sent to the Rapporteur, the Co-Rapporteur and other CVMP members. For Article 34(1) and Article 35 referrals initiated by the applicant(s)/marketing authorisation holder(s), the Agency will inform the applicant(s)/marketing authorisation holder(s) about the fees to be paid in accordance with Council Regulation (EC) No 297/95 on fees payable to the European Medicines Agency, as amended by Council Regulation (EC) No 1905/ Organisation of work within the CVMP/EMEA The CVMP appoints one of its members to act as Rapporteur. The appointment of a Rapporteur and, if appropriate, of a Co-Rapporteur is made by the CVMP on a case-by-case basis. In cases of a class referral, according to Article 35(2), it is not necessary to appoint a (Co-) Rapporteur for each veterinary medicinal product. One lead Rapporteur and more than one Co-Rapporteur(s) may be appointed for a class of products. Once the appointment of the (Co-) Rapporteur(s) has been made, the Agency informs the applicant(s)/marketing authorisation holder(s) and communicates also the name of the Agency Product Team Leader in charge. The CVMP may also appoint individual experts to advise it on specific questions. When it does so, the Committee defines their tasks and specifies the time limit for the completion of these tasks. For referrals triggered by a Member State or by the Commission, at the first CVMP meeting following the initiation of the referral, the CVMP formulates the question(s) to be addressed to the applicant(s)/marketing authorisation holder(s) and discusses, on the basis of the proposal from the party notifying the referral, the scope of the documentation actually requested or needed. For referrals triggered by the applicant(s)/marketing authorisation holder(s), at the fist CVMP meeting following the initiation of the referral, the CVMP starts its assessment of the issues referred. A list of questions may be adopted at day 30 of the procedure. 4 OJ L 304 of , p
13 The CVMP may also take into account any other information at its disposal which concerns the quality, safety and efficacy of the veterinary medicinal product(s) concerned and which may help in arriving at its opinion. It should be stressed that all members of the CVMP are equally concerned by the question submitted to the CVMP. They take part in the evaluation procedure and the adoption of opinion independently of the Member State, which has designated the CVMP member, and of the situation of the veterinary medicinal product in the Member States. 7.2 Hearing of the applicant/marketing authorisation holder Before issuing its opinion, the CVMP provides the applicant(s)/marketing authorisation holder(s) with an opportunity to present written or oral explanations. 7.3 Timetable and clockstop provisions After notification of the referral, the CVMP considers the matter and issues a reasoned opinion within 60 days of the date of the referral. For Article 34 and Article 35 referrals, the CVMP may extend that period to 150 days, taking into account the views of the applicant(s)/marketing authorisation holder(s). For all referrals, in case of urgency, on a proposal from its Chairperson, the CVMP may agree on a shorter deadline. The timepoints provided within the referral timetable below are given as the key steps in the referral procedure. They can be altered in order to reflect the particularities of a referral or to accommodate the interest of the company when needed. The timepoints refer to active days, i.e. correspond to the real time the CVMP takes to assess the data provided. The CVMP will not exceed the overall timeframe provided in the legislation. The CVMP may, however, suspend the time limit of 60/150 days (clock-stop) in order to allow the applicant(s)/marketing authorisation holder(s) to prepare the responses to a CVMP List of Questions, List of Outstanding Issues or an oral explanation (as appropriate). Referral triggered by a Member State or the Commission - Timetable for the procedure Day 0 Day 1 Clock stop Clock re-start (day 2) Notification of a referral to the CVMP/EMEA Secretariat First meeting of the CVMP following notification of referral. The CVMP discusses the question(s) referred during the plenary meeting. Rapporteur/(Co)-Rapporteur appointed/confirmed, as applicable Adoption of CVMP List of questions to be addressed by the MAHs/ applicant(s) and timetable For the MAHs/applicant(s) to answer CVMP List of questions Following submission of responses (in accordance with published submission dates) (and if applicable including English SPC, Labelling and PL) Adoption of CVMP timetable for the rest of the procedure Day 20 Rapporteur and Co-Rapporteur(s) circulate a report on the written responses from the applicant(s)/marketing Authorisation Holder(s) 13
14 together, if applicable, with the draft SPC/Labelling/PL to be annexed to the opinion Day 25 Day 30 Clock stop Clock re-start Day 60 Comments from CVMP members on the (Co-)Rapporteur(s) assessment report(s) and draft SPC/Labelling/PL (if applicable) Discussion at the CVMP: Adoption of the CVMP Opinion, or Adoption of CVMP List of outstanding issues to be answered in writing and/or in oral explanation If necessary, for the preparation and submission of written and/or oral explanations If necessary, following the submission of written explanations (in accordance with the published submission dates) and/or at the time of oral explanations Adoption of the CVMP opinion (with annexes as provided in Article 36 of Directive 2001/82/EC) Referral triggered by the applicant(s)/marketing authorisation holder(s) - Timetable for the procedure As in principle there is no list of questions at day 1 of the procedure, the timetable is as follows: Day 0 Notification of a referral to the CVMP/EMEA Secretariat Day 1 CVMP meeting following notification of referral and provided relevant documentation has been submitted by the MAH/Applicant in advance of the start of the procedure. The CVMP discusses the question(s) referred during the plenary meeting. Rapporteur/(Co)- Rapporteur appointed/confirmed. Adoption of the CVMP timetable. No adoption of List of questions. Day 20 Day 25 Day 30 Clock stop Clock re-start Day 60 Rapporteur and Co-Rapporteur(s) circulate assessment reports on the submission from the MAH(s)/applicant(s) and, if applicable, comments on the proposed SPC/Labelling/PL Comments from CVMP members on the (Co-)Rapporteur(s) assessment reports and draft SPC/Labelling/PL (if applicable) Discussion at the CVMP: Adoption of the CVMP Opinion, or Adoption of CVMP List of questions to be answered in writing and/or in oral explanation If necessary, for the preparation and submission of oral explanations If necessary, following the submission of written explanations (in accordance with the published submission dates) and/or at the time of oral explanations Adoption of the CVMP opinion (with annexes as provided in Article 36 of Directive 2001/82/EC) 14
15 7.4 CVMP opinion and re-examination mechanism The opinion of the CVMP may have implications for the applicant(s)/marketing authorisation holder(s), i.e., where the CVMP finds that: The application does not satisfy the criteria for authorisation, or The summary of the product characteristics proposed by the applicant(s)/ marketing authorisation holder(s) in accordance with Article 14 of Directive 2001/82/EC should be amended, or The authorisation should be granted subject to conditions, considered essential for the safe and effective use of the veterinary medicinal product including pharmacovigilance, or The marketing authorisation should be suspended, varied or revoked. Once the opinion of the CVMP is adopted, the Agency immediately informs the applicant(s)/ marketing authorisation holder(s). Within 15 days of the receipt of the opinion, the applicant(s)/marketing authorisation holder(s) may notify Agency in writing of his/their intention to request a re-examination of the opinion. In that case, he/they forward the detailed grounds for the request to the Agency within 60 days after receipt of the opinion. Within 60 days from receipt of the detailed grounds for the request, the CVMP shall reexamine its opinion. In order to do so, it will appoint a new Rapporteur and, where necessary, a new Co-Rapporteur different from those appointed for the initial opinion. The Rapporteur (and Co-Rapporteur where appropriate) is responsible for making an assessment of the detailed grounds for re-examination. Each of the grounds for re-examination should be dealt with separately and a reasoned conclusion on all relevant points must be included in the assessment report. If no request for re-examination is notified in writing to the Agency within 15 days of receipt of the opinion by the applicant(s)/marketing authorisation holder(s), the opinion automatically becomes a final opinion. 7.5 Final opinion Within 15 days of the adoption of the final opinion of the CVMP, the Agency forwards it to the Member States, the Commission and the applicant(s)/marketing authorisation holder(s) together with a report describing the assessment of the referral concerning the veterinary medicinal product(s) and stating the reasons for its conclusions. The conclusions of the re-examination are an integral part of the evaluation and should therefore be integrated within the final assessment report appended to the opinion and be reflected in scientific conclusions. In the event of an opinion in favour of granting, maintaining or varying a marketing authorisation for the veterinary medicinal product concerned, in accordance with Article 36(5) of Directive 2001/82/EC, the following documents are annexed to the opinion: i. List of the veterinary medicinal products and marketing authorisation holders concerned by the procedure; 15
16 ii. Draft summary of the product characteristics; iii. iv. Any conditions affecting the authorisation considered essential for the safe and effective use of the veterinary medicinal product including pharmacovigilance, if applicable; Details of any recommended conditions or restrictions with regard to the safe and effective use of the veterinary medicinal product, if applicable; v. The proposed text of the labelling and package leaflet; vi. Scientific conclusions justifying the outcome of the referral. In the cases of an Article 33 or Article 35(2) referral where only parts of the summary of products characteristics and the corresponding parts of the labelling and package leaflet are harmonised only these will be annexed to the opinion. The same may apply in case of followup referrals. Furthermore, in those situations where no amendments to the summary of products characteristics, labelling or package leaflet are foreseen, the annex shall include a statement to that effect. In the event of an opinion recommending the suspension or revocation of the marketing authorisation(s) for the veterinary medicinal product concerned, the scientific conclusions and grounds for suspension or revocation of the marketing authorisation are annexed to the opinion, as well as the conditions for the lifting of the suspension Conditions and restrictions with regard to the safe and effective use of the veterinary medicinal product addressed to the applicant/marketing authorisation holder according to Article 36(4)(third indent) and (5)(b) and (c) of Directive 2001/82/EC In the cases foreseen in Article 36(4)(third indent) and (5)(b) and (c) of Directive 2001/82/EC the authorisation should be granted subject to certain conditions, in view of conditions considered essential for the safe and effective use of the veterinary medicinal product including pharmacovigilance or other recommended conditions or restrictions with regard to the safe and effective use of the veterinary medicinal product. The opinion/assessment report of the CVMP should thus include justification for the conditions proposed, i.e. timelines to be kept and details of the reports, including the details for the pharmacovigilance reports to be presented to guarantee a sufficient follow-up of the marketing authorisation. The follow-up to the conditions will normally be monitored by the Member States and only in exceptional cases by the CVMP. 8. Decision making procedure at Community level After the reception of the final opinion of the CVMP, the Commission starts the Community decision-making procedure. For a detailed description of this procedure, see chapter 6. The decision will be reported for information to the applicant(s)/marketing authorisation holder(s). The Member States are required to either grant, maintain, suspend, or withdraw/revoke the marketing authorisation, or vary the terms of the marketing authorisation as necessary to comply with the decision within 30 days of its notification and are required to inform the Commission and the Agency of the measures taken. 16
17 When the decision provides for granting or maintaining a marketing authorisation, the documents annexed to the decision are: the list of the names, pharmaceutical forms, strengths and routes of administration of the veterinary medicinal product and its applicants/marketing authorisation holders in the Member States, the summary of product characteristics, the text of the labelling and package leaflet, the scientific conclusions and, as the case may be, any condition affecting the authorisation considered essential for the safe and effective use of the veterinary medicinal product including pharmacovigilance, and any conditions or restrictions with regard to the safe and effective use of the veterinary medicinal product. When the decision provides for the suspension of the marketing authorisation, the conditions for the lifting of the suspension will also be annexed. 9. Consequences of a commission decision following a referral to the CVMP Member States national requirements for the implementation of a referral decision, as well as details on the national procedure(s) to be followed to the Commission decision are included in Chapter 7, section Actions to be taken by the Member States after a referral Commission decisions following a procedure are addressed to all Member States. Commission decisions taken following a request Member States directly concerned by the referral procedure to comply with the Community decision within 30 days of its notification and to inform the Commission and the Agency. The marketing authorisation holder is urged to take appropriate steps necessary to allow the Member States to comply with the Community decision within 30 days after its notification, for instance by timely proving any necessary translations. After a referral procedure with a positive opinion concerning granting or the maintenance of a marketing authorisation, Member States concerned by the procedure must vary the terms of the marketing authorisation, as necessary, to comply with the decision of the Commission within 30 days after its notification. When the opinion is that a marketing authorisation must be suspended or withdrawn/revoked, Member States where the veterinary medicinal product is authorised shall suspend or withdraw/revoke the marketing authorisation. The same applies when the opinion of the Committee is that a marketing authorisation must be refused. In those Member States not directly concerned by the procedure, no immediate action is necessary since there are no pending applications or marketing authorisations for the veterinary medicinal product(s) in question. These Member States, however, as addressees of the decision, should consider whether any action is appropriate as regards products authorised by them, and should take the decision into account in any future regulatory action. Member States should also consider appropriate action in case the referred veterinary medicinal product has been subject to multiple applications for marketing authorisation. In the case of a subsequent application for the same veterinary medicinal product, the evaluation must take into account the Commission decision and Member States should grant or refuse the national marketing authorisations according to the terms of the Commission 17
18 decision unless there are potential serious risks to human or animal health or to the environment or issues which have not been previously considered. Any Member State or the Commission would as appropriate refer the new scientific issue to the CVMP in order to start a new referral procedure. The same applies in case where a marketing authorisation is pending for the veterinary medicinal product, which was the subject of the referral. The Member States must grant or refuse national marketing authorisations in accordance with the Commission decision. 9.2 Independent applications for marketing authorisation submitted during a referral procedure While a referral procedure is ongoing, independent applications for marketing authorisation concerning veterinary medicinal products with the same active substance(s) can be submitted. For instance, if an Article 34 referral concerns the originator veterinary medicinal product, applications for generic veterinary medicinal products of this originator veterinary medicinal product may be submitted. However, where independent applications for products with the same active substance are submitted once a referral is ongoing, Member States should consider the outcome of the referral as far as it may be relevant for the assessment of such applications. The same occurs in the frame of Article 35 class referrals, if applications for marketing authorisations of veterinary medicinal products of the same class or range are submitted. Applications for variations can be submitted and ongoing procedures can be finalised, even if the veterinary medicinal product is involved in a referral. However, when a referral procedure based on Article 33 is ongoing it is recommended that no new variation procedure is started for the veterinary medicinal product concerned, unless it relates to human or animal health or environmental matters. 9.3 Subsequent applications occurring after finalisation of the referral Subsequent applications for a specific veterinary medicinal product which has been the subject of a referral must use the harmonisation achieved following the referral. After Articles 33, 34 and 35 referrals subsequent applications for the same veterinary medicinal product must be submitted through the mutual recognition or decentralised procedure and must be mutually recognised in accordance with the relevant Commission decisions unless a new referral is triggered with respect to a new potential serious risk to human or animal health or the environment. In accordance with Articles 12(3)(n) and 22 of Directive 2001/82/EC and Commission Communication C98/229/03, the mutual recognition procedure will also apply if the same company, or a company from the same group of companies, applies for a separate marketing authorisation for the product, regardless of whether the product has been the subject of full harmonisation. However with regard to the Article 34 and Article 35 referrals there are some particularities that should be noted. Where the referral leads to harmonisation (with the exception of partial harmonisation, as explained in section 4.4.2), the mutual recognition procedure has to be followed afterwards, in order to maintain the achieved harmonisation. Where the procedure is limited to certain specific parts of the authorisation, the obligation to follow a mutual recognition procedure only applies if the marketing authorisations were granted initially by the decentralised or mutual recognition procedure. In this case, the 18
CHAPTER 3. September 2007
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, ENTR/F2/SM D(2007) Revision September 2007 NOTICE TO APPLICANTS VOLUME 2A Procedures for marketing
More informationCHAPTER 3. Union Referral Procedures MAY 2014
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products Brussels, Revision May 2014 NOTICE TO APPLICANTS VOLUME 2A Procedures for marketing authorisation
More information(Legislative acts) REGULATIONS
31.12.2010 Official Journal of the European Union L 348/1 I (Legislative acts) REGULATIONS REGULATION (EU) No 1235/2010 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 15 December 2010 amending, as regards
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
The European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 15 December 2005 EMEA/357981/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON PROCEDURES
More information(Acts whose publication is obligatory) REGULATION (EC) No 726/2004 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004
30.4.2004 Official Journal of the European Union L 136/1 I (Acts whose publication is obligatory) REGULATION (EC) No 726/2004 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 2004 laying down
More informationGuideline on the processing of renewals in the centralised procedure
14 July 2016 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation December 2000
More informationThis is an unofficial English translation of the Royal Decree 1344/2007 revised by the Spanish Agency for Medicines and Medical Devices
agencia española de medicamentos y productos sanitarios This is an unofficial English translation of the Royal Decree 1344/2007 revised by the Spanish Agency for Medicines and Medical Devices ROYAL DECREE
More informationDIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004
30.4.2004 Official Journal of the European Union L 136/85 DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 2004 amending, as regards traditional herbal medicinal products,
More informationNOTICE TO APPLICANTS
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Food and feed safety, innovation Animal nutrition, veterinary medicines NOTICE TO APPLICANTS VETERINARY MEDICINAL PRODUCTS VOLUME 6A Procedures
More informationGuideline on influenza vaccines submission and procedural requirements
1 2 3 October 2014 EMA/56793/2014 Human Medicines Research and Development Support 4 5 6 Guideline on influenza vaccines submission and procedural requirements Regulatory and procedural requirements module
More informationREGULATION (EC) No.141/2000
REGULATION (EC) No.141/2000 Community legislation in force Document 300R0141 Directory chapters where this document can be found: [15.30 Health promotion] Regulation (EC) No.141/2000 of the European Parliament
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 26 July 2006 Doc. Ref. EMEA/186279/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON LEGAL STATUS FOR THE SUPPLY TO THE PATIENT OF CENTRALLY AUTHORISED
More informationC 178/2 Official Journal of the European Union
C 178/2 Official Journal of the European Union 29.7.2003 Communication from the Commission on Regulation (EC) No 141/2000 of the European Parliament and of the Council on orphan medicinal products (2003/C
More informationProcedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure
1 2 3 4 5 6 7 8 9 14 April 2010 EMA/CHMP/BWP/99698/2007 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) Procedural advice on the submission of variations for annual update of human influenza
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES. Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
EN EN EN COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 10.12.2008 COM(2008) 664 final 2008/0257 (COD) Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL amending, as regards pharmacovigilance
More informationREGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011.
REGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011. CHAPTER I Scope and definitions. Article 1 Scope.
More informationA GUIDELINE ON CHANGING THE CLASSIFICATION FOR THE SUPPLY OF A MEDICINAL PRODUCT FOR HUMAN USE
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Revision January 2006 A GUIDELINE ON CHANGING THE CLASSIFICATION FOR THE SUPPLY OF A MEDICINAL PRODUCT FOR
More informationCOUNCIL OF THE EUROPEAN UNION. Brussels, 7 September 2009 (OR. en) 11261/09 Interinstitutional File: 2008/0002 (COD) DENLEG 51 CODEC 893
COUNCIL OF THE EUROPEAN UNION Brussels, 7 September 2009 (OR. en) 11261/09 Interinstitutional File: 2008/0002 (COD) DLEG 51 CODEC 893 LEGISLATIVE ACTS AND OTHER INSTRUMTS Subject: Common Position with
More informationOther EU Activities Contributing to Harmonization of Labeling
Other EU Activities Contributing to Harmonization of Labeling Dr Laurent Brassart European Medicines Agency Medical Information Sector DIA Labeling Harmonisation 2011 Workshop October 13-14. 2011 Disclaimer
More informationThis document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
1997R0258 EN 07.08.2009 004.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B REGULATION (EC) No 258/97 OF THE EUROPEAN PARLIAMENT
More informationCODE OF STATUTES MEDICAL PRODUCTS AGENCY
CODE OF STATUTES MEDICAL PRODUCTS AGENCY Publisher: Christina Åkerman, Director-General. LVFS 2012:19 Published 4 July 2012. The Medical Products Agency s Provisions on Parallel Imported Medicinal Products;
More informationEUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL. PHARMACEUTICAL COMMITTEE 21 October 2015
EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, European Medicines Agency PHARM 689 PHARMACEUTICAL COMMITTEE 21 October 2015
More informationThis Administrative regulation will come into force on 1 st January 2018 and will remain so until further notice. Administrative Regulation No 3/2015
Administrative regulation 15.12.2017 Dnro 007313/00.01.02/2017 02/2017 UNOFFICIAL TRANSLATION Finnish Medicines Agency Administrative Regulation APPLYING FOR AND MAINTAINING A MARKETING AUTHORI- SATION
More informationEUROPEAN UNION. Brussels, 15 October 2007 (OR. en) 2005/0227 (COD) PE-CONS 3627/07 MI 149 ECO 83 SAN 123 CODEC 621
EUROPEAN UNION THE EUROPEAN PARLIAMT Brussels, 15 October 2007 (OR. en) THE COUNCIL 2005/0227 (COD) PE-CONS 3627/07 MI 149 ECO 83 SAN 123 CODEC 621 LEGISLATIVE ACTS AND OTHER INSTRUMTS Subject: Regulation
More informationSecretary-General of the European Commission, signed by Mr Jordi AYET PUIGARNAU, Director
COUNCIL OF THE EUROPEAN UNION Brussels, 13 February 2014 (OR. en) 6438/14 COVER NOTE From: date of receipt: 3 February 2014 To: No. Cion doc.: PHARM 14 SAN 72 MI 161 COMPET 107 DELACT 29 Secretary-General
More informationOctober 2003 Revision 1, February INTRODUCTION AND SCOPE
BEST PRACTICE GUIDE FOR THE EXCHANGE OF REGULATORY AND ADMINISTRATIVE INFORMATION REGARDING ORPHAN MEDICINAL PRODUCTS BETWEEN THE EMEA AND THE NATIONAL COMPETENT AUTHORITIES October 2003 Revision 1, February
More informationThis document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
2007R1394 EN 02.07.2012 001.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B REGULATION (EC) No 1394/2007 OF THE EUROPEAN
More informationEMEA WORKING PARTY ON HERBAL MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use 25 October 1999 EMEA/HMPWP/23/99 EMEA WORKING PARTY ON HERBAL MEDICINAL PRODUCTS UPDATED DRAFT POINTS
More informationAGREEMENT ON COMMON PRINCIPLES AND RULES OF CIRCULATION OF MEDICINAL PRODUCTS WITHIN THE EURASIAN ECONOMIC UNION. (Moscow, 23 December 2014)
AGREEMENT ON COMMON PRINCIPLES AND RULES OF CIRCULATION OF MEDICINAL PRODUCTS WITHIN THE EURASIAN ECONOMIC UNION (Moscow, 23 December 2014) Member States of the Eurasian Economic Union, hereinafter referred
More informationGuideline on good pharmacovigilance practices (GVP)
19 April 2013 EMA/169546/2012 Guideline on good pharmacovigilance practices (GVP) Module X Additional monitoring Draft finalised by the Agency in collaboration with Member States 25 May 2012 Draft agreed
More informationThis Administrative regulation will come into force on 1 st August 2013 and will remain so until further notice.
Administrative regulation 01.08.2013 Dnro 4000/03.01.01/2012 2/2013 UNOFFICIAL TRANSLATION Finnish Medicines Agency Administrative Regulation APPLYING FOR AND MAINTAINING A MARKETING AUTHORI- SATION AND
More informationMedicinal Products for Human Use HOMEOPATHIC MEDCINAL PRODUCT FOR HUMAN USE. December 2005
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, F2/BL D(2005) NOTICE TO APPLICANTS Medicinal Products for Human Use VOLUME 2B Presentation and content
More informationThe European Medicines Agency (EMA)
The European Medicines Agency (EMA) Nathalie Bere Patient Relations Public Engagement Department EMA Training Day 29 November, 2016 An agency of the European Union What is the European Medicines Agency
More informationDraft Regulations on granting of licences for parallel import of medicinal products
REGULATION on granting of licences for parallel import of medicinal products for human use and veterinary use. Art. 1. Scope and definitions. This regulation applies to granting of parallel import licences
More informationGuide to Interchangeable Medicines
Guide to Interchangeable Medicines AUT-G0115-6 01 JUNE 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS 1 BACKGROUND 3 1.1
More informationEMEA PANDEMIC INFLUENZA CRISIS MANAGEMENT PLAN FOR THE EVALUATION AND MAINTENANCE OF PANDEMIC INFLUENZA VACCINES AND ANTIVIRALS
European Medicines Agency London, 21 August 2006 Doc. Ref. EMEA/214301/2006 EMEA PANDEMIC INFLUENZA CRISIS MANAGEMENT PLAN FOR THE EVALUATION AND MAINTENANCE OF PANDEMIC INFLUENZA VACCINES AND ANTIVIRALS
More informationMEDICINES ACT 395/1987. Unofficial translation; Amendments up to 1340/2010 included
MEDICINES ACT 395/1987 Unofficial translation; Amendments up to 1340/2010 included Chapter 1 General provisions Objectives Section 1 (80/2003) The objective of this Act is to maintain and promote the safety
More informationEFSA PRE-SUBMISSION GUIDANCE FOR APPLICANTS INTENDING TO SUBMIT APPLICATIONS FOR AUTHORISATION OF HEALTH CLAIMS MADE ON FOODS
EFSA PRE-SUBMISSION GUIDANCE FOR APPLICANTS INTENDING TO SUBMIT APPLICATIONS FOR AUTHORISATION OF HEALTH CLAIMS MADE ON FOODS Last updated (Rev.): 21 December 2007 Publication Date: 14 March 2007 NOTES
More informationHolders of European Union marketing authorizations
PRAC Experience The legal framework The Pharmacovigilance legislation (Regulation No 1235/2010 and Directive 2010/84/EU) was adopted by the European Parliament and European Council in December 2010. The
More informationCOMMISSION REGULATION (EU)
11.3.2011 Official Journal of the European Union L 64/15 COMMISSION REGULATION (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the European Parliament and of the Council
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT
EN EN EN COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 5.12.2008 COM(2008) 824 final REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT on the use of substances other than vitamins
More informationOverview of the Procedure and interactions between CAT and CHMP
1 st Workshop on Advance Therapy Medicinal Products (ATMPs) Overview of the Procedure and interactions between CAT and CHMP Marie-Helene Pinheiro EMEA Regulatory Affairs Insert your logo in this area then
More informationCOUNCIL OF THE EUROPEAN UNION. Brussels, 15 November 2005 (OR. en) 9858/05 Interinstitutional File: 2003/0165 (COD) DENLEG 25 SAN 105 CODEC 481 OC 382
COUNCIL OF THE EUROPEAN UNION Brussels, 15 November 2005 (OR. en) 9858/05 Interinstitutional File: 2003/0165 (COD) DLEG 25 SAN 105 CODEC 481 OC 382 LEGISLATIVE ACTS AND OTHER INSTRUMTS Subject: COMMON
More informationWorkshop for OIE national Focal Points for Veterinary Products November 2010, Johannesburg, South Africa. Presentation
Dr. Anja Holm Chair of CVMP, EMA Danish Medicines Agency Copenhagen, DK - Denmark anh@dkma.dk Overview of existing structures relevant for Veterinary Products Regional Structures: Europe European Medicine
More informationStandard operating procedure
Standard operating procedure Title: Article 29(4) referral procedures (MRP/DCP referrals) Status: PUBLIC Document no.: SOP/H/3177 Lead author Approver Effective date: 04-SEP-12 Name: Thomas Larsson Name:
More informationAnnex II. Scientific conclusions
Annex II Scientific conclusions Scientific conclusions Between 29 September 2015 and 9 October 2015, the United States Food and Drug Administration (FDA) performed a Good Clinical Practice (GCP) inspection
More informationState of Connecticut Department of Education Division of Teaching and Learning Programs and Services Bureau of Special Education
State of Connecticut Department of Education Division of Teaching and Learning Programs and Services Bureau of Special Education Introduction Steps to Protect a Child s Right to Special Education: Procedural
More informationMedical Devices Act 1
Issuer: Riigikogu Type: act In force from: 01.01.2016 In force until: 31.05.2016 Translation published: 01.02.2016 Medical Devices Act 1 Amended by the following acts Passed 13.10.2004 RT I 2004, 75, 520
More informationThe EU PIP - a step in Pediatric Drug Development. Thomas Severin Bonn,
The EU PIP - a step in Pediatric Drug Development Thomas Severin Bonn, 13.01.2009 Agenda Implications for Industry Company Preparation Time of PIP Submission Content of the PIP The PIP Process and first
More informationEUR-Lex L EN. Council Directive 93/74/EEC of 13 September 1993 on feedingstuffs intended for particular nutritional purposes
Page 1 of 5 Avis juridique important 31993L0074 Council Directive 93/74/EEC of 13 September 1993 on feedingstuffs intended for particular nutritional purposes Official Journal L 237, 22/09/1993 P. 0023-0027
More informationThe Committee for Medicinal Products for Human Use
www.eurordis.org The Committee for Medicinal Products for Human Use Patrick Salmon HPRA Barcelona, 4th June, 2015 2 CHMP 3 CHMP Move 4 The New CHMP 5 Where it all happens! 6 CHMP... What is it? CHMP What
More informationSUMMARY REPORT OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH HELD IN BRUSSELS ON 10 DECEMBER 2012 (Section General Food Law)
EUROPEAN COMMISSION HEALTH & CONSUMERS DIRECTORATE-GENERAL Brussels, SANCO E 1718316 SUMMARY REPORT OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH HELD IN BRUSSELS ON 10 DECEMBER 2012 (Section
More informationSTANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH SECTION ON GENERAL FOOD LAW. Summary Record of Meeting of 30 April 2012
EUROPEAN COMMISSION HEALTH & CONSUMERS DIRECTORATE-GENERAL STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH SECTION ON GENERAL FOOD LAW Summary Record of Meeting of 30 April 2012 Chairmen: Mr Basil
More informationDRAFT COMMISSION DELEGATED REGULATION (EU) /... of XXX
EUROPEAN COMMISSION Brussels, XXX C(2016) 3752 projet DRAFT COMMISSION DELEGATED REGULATION (EU) /... of XXX setting out scientific criteria for the determination of endocrine-disrupting properties pursuant
More informationCOMMISSION REGULATION (EU) / of XXX
Ref. Ares(2016)5616438-28/09/2016 EUROPEAN COMMISSION Brussels, XXX [ ](2016) XXX draft COMMISSION REGULATION (EU) / of XXX amending Annex III to Directive 2008/98/EC of the European Parliament and of
More informationEUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL VOLUME 2C. Guidelines. Medicinal products for human use
EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Brussels, Draft Revision 2 NOTICE TO APPLICANTS VOLUME 2C Guidelines Medicinal products for human use Safety, environment and information
More informationAdopted by CVMP 10 March Date for coming into effect 1 July Revised draft guideline agreed by Immunologicals Working Party 22 June 2017
1 2 3 7 September 2017 EMA/CVMP/IWP/105506/2007-Rev.1 Committee for medicinal products for veterinary use (CVMP) 4 5 6 7 Guideline on data requirements for multi-strain dossiers for inactivated vaccines
More informationDIRECTIVES. (Text with EEA relevance)
L 238/44 DIRECTIVES COMMISSION DIRECTIVE (EU) 2017/1572 of 15 September 2017 supplementing Directive 2001/83/EC of the European Parliament and of the Council as regards the principles and guidelines of
More informationStandard operating procedure
Standard operating procedure Title: Preparation of an initial European Public Assessment Report (EPAR) for a human medicinal product following positive or negative opinion Status: PUBLIC Document no.:
More informationProcedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products
25 June 2013 rev. 1 1. Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human 1 Editorial revisions have been made to the table of
More informationIMPORTANT DISCLAIMER. Note
yn EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL June 2012 DRAFT GUIDANCE DOCUMENT FOR COMPETENT AUTHORITIES FOR THE CONTROL OF COMPLIANCE WITH EU LEGISLATION ON: Regulation (EU) No 1169/2011
More informationDraft Agreed by Immunologicals Working Party January Adoption by CVMP for release for consultation 12 March 2009
15 March 2010 EMA/CVMP/IWP/105506/2007 Committee for medicinal products for veterinary use (CVMP) Guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza
More informationReport from the CMD(h) meeting held from 20 th to 22 nd March 2006
Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human General Issues Report from the CMD(h) meeting held from 20 th to 22 nd March 2006 Meeting on Harmonisation of SPCs with Interested
More informationEuropean Medicines Agency decision
EMA/151867/2018 European Medicines Agency decision P/0107/2018 of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (Fasenra), (EMEA-001214-PIP01-11-M07)
More informationWorking Document prepared by the Commission services - does not prejudice the Commission's final decision 3/2/2014 COMMISSION STAFF WORKING DOCUMENT
COMMISSION STAFF WORKING DOCUMENT on certain requirements for FSMPs [Supporting Document for the Expert Group meeting of 7 February 2014] Introduction Following the discussions in the Expert Group meeting
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES. Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
EN EN EN COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 10.12.2008 COM(2008) 663 final 2008/0256 (COD) Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL amending, as regards information
More informationGuideline on the acceptability of names for human medicinal products processed through the centralised procedure
1 2 3 07 June 2013 CPMP/328/98, Revision 6 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the acceptability of names for human medicinal products processed through the centralised
More informationon the approximation of the laws of the Member States concerning food additives authorized for use in foodstuffs intended for human consumption
11. 2. 89 Official Journal of the European Communities No L 40/ 27 COUNCIL DIRECTIVE of 21 December 1988 on the approximation of the laws of the Member States concerning food additives authorized for use
More informationPractical guidance for applicants on the submission of applications on food additives, food enzymes and food flavourings
Version 2 Updated on 29/11/2011 Practical guidance for applicants on the submission of applications on food additives, food enzymes and food flavourings Valid as of: 11 September 2011 Disclaimer: This
More informationEuropean Medicines Agency decision
EMA/848760/2017 European Medicines Agency decision P/0033/2018 of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M10)
More informationDE-DESIGNATION OF YELLOW FEVER VACCINATION CENTRES
DE-DESIGNATION OF YELLOW FEVER VACCINATION CENTRES January 2014 INDEX Page 1. Introduction 3 2. De-designating a YFVC 4 3. The de-designation process 5-6 4. Repeated breaches of the standards for designation
More informationLaura Beatriz Herrero Montarelo, Maria Dolores Gómez Vázquez and Victorio José Teruel Muñoz
Collaboration Laura Beatriz Herrero Montarelo, Maria Dolores Gómez Vázquez and Victorio José Teruel Muñoz Nutritional Risk Management Area of the Subdirectorate-General for Food Safety Promotion Spanish
More informationAccess to electronic communications services for disabled customers
Access to electronic communications services for disabled customers Statement Publication date: 12 March 2014 Contents Section Page 1 Summary 1 2 Introduction 2 3 Access to and pricing of the relay service
More informationMifepriston Linepharma. Mifepristone Linepharma. Mifepristone Linepharma 200 mg comprimé. Mifepristone Linepharma 200 mg Tafla
Annex I List of the names, pharmaceutical form, strength of the medicinal products, route of administration, applicants /marketing authorisation holders in the Member States 1 Member State EU/EEA Marketing
More informationStandard Operating Procedure. Selection of studies performed in compliance with Good Laboratory Practice for audit purposes
Scope To describe the procedure for EFSA to request on a yearly or ad-hoc basis the performance of GLP studies audits by the GLP Monitoring Authorities. To lay down criteria for the selection of the GLP
More informationSTATUTORY INSTRUMENTS. S.I. No. 531 of 2018 HEALTH PRODUCTS REGULATORY AUTHORITY (FEES) (NO. 2) REGULATIONS 2018
STATUTORY INSTRUMENTS. S.I. No. 531 of 2018 HEALTH PRODUCTS REGULATORY AUTHORITY (FEES) (NO. 2) REGULATIONS 2018 2 [531] S.I. No. 531 of 2018 HEALTH PRODUCTS REGULATORY AUTHORITY (FEES) (NO. 2) REGULATIONS
More informationXOSERVE LIMITED SERVICES SCHEDULE FOR THE PROVISION OF NON-CODE USER PAYS SERVICES (REFERENCE NUMBER XNCUP(SS)06) DATED 20 INTRODUCTION
XOSERVE LIMITED SERVICES SCHEDULE FOR THE PROVISION OF NON-CODE USER PAYS SERVICES (REFERENCE NUMBER XNCUP(SS)06) DATED 20 INTRODUCTION 1 This services schedule forms part of the framework contract for
More information2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary
European Medicines Agency London, 17 March 2009 Doc. Ref. EMEA/43556/2009 2008 Status Report on the Implementation of the European Risk Management Strategy Executive Summary The European Risk Management
More informationOfficial Journal of the European Union
L 66/26 11.3.2003 DIRECTIVE 2003/15/EC OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 27 February 2003 amending Council Directive 76/768/EEC on the approximation of the laws of the Member States relating
More informationSection 32: BIMM Institute Student Disciplinary Procedure
Section 32: BIMM Institute Student Disciplinary Procedure Introduction Academic Development & Quality Assurance Manual This Student Disciplinary Procedure provides a framework for the regulation of BIMM
More informationEuropean Medicines Agency decision
EMA/501681/2016 European Medicines Agency decision P/0213/2016 of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (EMEA- 001214-PIP01-11-M05)
More informationEUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL VOLUME 2C. Guidelines. Medicinal products for human use
EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Brussels, March 2018 SANTE-2017-11668 Revision 2 NOTICE TO APPLICANTS VOLUME 2C Guidelines Medicinal products for human use Safety, environment
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL
Ref. Ares(2015)5296129-23/11/2015 EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Chemicals, Metals, Forest-based & Textile Industries Chemicals Brussels, 18 September 2007 ENTR/G2/KGR
More informationEuropean Medicines Agency decision
EMA/497687/2017 European Medicines Agency decision P/0245/2017 of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 16 February 2006 Doc. Ref.EMEA/CVMP/IWP/46853/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REFLECTION PAPER: MINIMUM
More informationCOMMISSION IMPLEMENTING DECISION. of
EUROPEAN COMMISSION Brussels, 14-04-2011 C(2011)2799 COMMISSION IMPLEMENTING DECISION of 14-04-2011 granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of
More informationGUIDELINE ON THE CATEGORISATION OF EXTENSION APPLICATIONS (EA) versus VARIATIONS APPLICATIONS (V) OCTOBER 2003
EUROPN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, implementation and legislation for consumer goods Pharmaceuticals : regulary framework and market authorisations Brussels, F2/AW D(2002)
More informationFrequently asked questions
13 February 2017 EMA/527628/2011 Rev. 1 Directorate This document provides answers to the most frequently asked questions received by the European Medicines Agency (EMA).If the answer to your question
More informationCOMMISSION DELEGATED REGULATION (EU).../... of XXX
EUROPEAN COMMISSION Brussels, XXX SANTE/10355/2015 (POOL/E4/2015/10355/10355-EN. doc) [...1(2015) XXX draft COMMISSION DELEGATED REGULATION (EU).../... of XXX supplementmg Regulation (EU) No 609/2013 of
More informationInternational Standard for Athlete Evaluation. July 2015
International Standard for Athlete Evaluation July 2015 International Paralympic Committee Adenauerallee 212-214 Tel. +49 228 2097-200 www.paralympic.org 53113 Bonn, Germany Fax +49 228 2097-209 info@paralympic.org
More informationDIRECTIVE 2011/62/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
L 174/74 Official Journal of the European Union 1.7.2011 DIRECTIVE 2011/62/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to
More informationOfficial Journal of the European Union L 109/11
19.4.2008 Official Journal of the European Union L 109/11 COMMISSION REGULATION (EC) No 353/2008 of 18 April 2008 establishing implementing rules for applications for authorisation of health claims as
More informationBACKGROUND + GENERAL COMMENTS
Response on behalf of Sobi (Swedish Orphan Biovitrum AB) to the European Commission s Public Consultation on a Commission Notice on the Application of Articles 3, 5 and 7 of Regulation (EC) No. 141/2000
More informationMETROLINX ADMINISTRATIVE FEE DISPUTE RESOLUTION PROCESS RULES OF PRACTICE
METROLINX ADMINISTRATIVE FEE DISPUTE RESOLUTION PROCESS RULES OF PRACTICE Overview The Metrolinx Act, 2006, gives Metrolinx ( Metrolinx ) the authority to establish a system of administrative fees to ensure
More informationThe European Medicines Agency (EMA)
The European Medicines Agency (EMA) Nathalie Bere and Maria Mavris Public Engagement Department EMA Training Day 21 November, 2017 An agency of the European Union What is the European Medicines Agency
More informationRECERTIFICATION PROGRAMME FOR CONTINUING PROFESSIONAL DEVELOPMENT OF OPTOMETRISTS
RECERTIFICATION PROGRAMME FOR CONTINUING PROFESSIONAL DEVELOPMENT OF OPTOMETRISTS Background The principal purpose of the Health Practitioners Competence Assurance Act 2003 (Act) is to protect public health
More informationCOMPETENT AUTHORITY (UK) MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES
COMPETENT AUTHORITY (UK) 10 EC MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES (CUSTOM MADE DEVICES) Updated March 2008 CONTENTS PAGE Introduction 3 Definition of dental
More informationAnnex II. Scientific conclusions
Annex II Scientific conclusions 7 Scientific conclusions Overall summary of the scientific evaluation of methadone products for oral use containing povidone Methadone is a synthetic opioid. Methadone is
More information